Last reviewed · How we verify
NCT07053579
Cross-cultural Adaptation and Validation of the P-CIN for Chinese Pediatric Oncology Patients
trial in Pediatric Cancer in 313 participants. Completed in 30 May 2025.
30 May 2025
Quick facts
| Lead sponsor | The Hong Kong Polytechnic University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 313 |
| Start date | 5 January 2025 |
| Primary completion | 30 May 2025 |
| Estimated completion | 30 May 2025 |
| Sites | 2 locations across Hong Kong |
Conditions studied
- Pediatric Cancer — all drugs for Pediatric Cancer →
Sponsor
The Hong Kong Polytechnic University
Who can join
Adults 6 to 18, any sex, with Pediatric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study was to conduct a cross-cultural adaptation of the P-CIN into the Chinese context, assess its psychometric properties, and determine the cut-off value of CIPN among Chinese pediatric oncology patients. Participants provided demographic and clinical characteristics, and complete the translated P-CIN, Wong-baker FACES Pain Rating scale for pain, and Chinese version of the Pediatric Quality of Life Inventory (PedsQL) Cancer Module for quality of life.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cross-cultural adaptation and validation of the Pediatric Chemotherapy-Induced Neuropathy (P-CIN) using a patient-reported outcome measure for Chinese pediatric oncology patients.
Mao T, Yorke J, Shi Y, Shen N, et al · · 2026 · PMID 41862927 · DOI 10.1186/s12955-026-02509-9
Verify or expand the search:
- PubMed search for NCT07053579
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pediatric Cancer
Currently open trials in the same condition.
- NCT07506239 — Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma · NA · recruiting
- NCT07278778 — Cancer Care Companion · NA · recruiting
- NCT07473518 — Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy · recruiting
- NCT06939322 — LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) · NA · recruiting
- NCT07188311 — Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma · NA · recruiting
Other The Hong Kong Polytechnic University trials
Trials by the same sponsor.
- NCT07505732 — Information-providing Chatbot · NA · not yet recruiting
- NCT07391449 — Heart Rate Variability Guided Physical Activity and Exercise Prescription in Individuals With Knee Osteoarthritis · NA · not yet recruiting
- NCT07450248 — The Use of Telephone-based ACT for Quitting Alcohol in the Young Population With Hazardous or Harmful Alcohol Use. · NA · not yet recruiting
- NCT07273682 — Nurse-led Transitional Care to Improve Symptom Management in Childhood Cancer Survivors · NA · not yet recruiting
- NCT07531082 — Effects of a Salutogenic Strength-based Social Robot-assisted Intervention on the Depressive Symptoms and Sense of Coher · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07053579 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Hong Kong Polytechnic University
- Last refreshed: 8 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07053579.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing